Description: Cardiol Therapeutics Inc. (TSX: CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (“CVD”). The Company’s lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. This potentially registrational trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease. Cardiol has filed an investigational new drug (“IND”) application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure – a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.
Home Page: www.cardiolrx.com
CRDL Technical Analysis
2265 Upper Middle Road East
Oakville,
ON
L6H 0G5
Canada
Phone:
289 910 0850
Officers
| Name | Title |
|---|---|
| Mr. David G. Elsley M.B.A., MBA | Pres, CEO & Director |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA | CFO, Corp. Sec. & Director |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of R&D |
| Trevor Burns | Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0556 |
| Price-to-Sales TTM: | 1069.351 |
| IPO Date: | 2019-01-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |